Novyra Pharmachem: No Deviation in Funds Utilization

Novyra Pharmachem Limited (formerly Bansisons Tea Industries Ltd) confirms no deviation or variation in the utilization of funds raised under preferential issue, as per Regulation 32 of SEBI guidelines. The report, filed for the quarter and year ended March 31, 2026, states that the ₹13,24,500 raised from 1,76,600 partly paid-up shares on June 9, 2025, was utilized as originally intended for working capital requirements. The Audit Committee and auditors have reviewed and found no deviations.